{
    "clinical_study": {
        "@rank": "11679", 
        "arm_group": [
            {
                "arm_group_label": "Never Smokers", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Current/former Smokers", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "This study will evaluate the efficacy and safety of Tarceva in two groups of patients with\n      non-small cell lung cancer who have not been pre-treated with chemotherapy. One group,\n      consisting of patients who have never smoked, will receive Tarceva 150mg/day, and the other\n      group, consisting of current/former smokers, will receive Tarceva 150mg/day increasing to a\n      maximum of 300mg/day. The anticipated time on study treatment is 1-2 years."
        }, 
        "brief_title": "A Study of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer Naive to Chemotherapy", 
        "completion_date": {
            "#text": "December 2010", 
            "@type": "Actual"
        }, 
        "condition": "Non-Small Cell Lung Cancer", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma, Non-Small-Cell Lung", 
                "Lung Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  adult patients, >=18 years of age;\n\n          -  histologically documented advanced non-small cell lung cancer (stage IIIB/IV);\n\n          -  ECOG performance status 0-2;\n\n          -  no previous chemotherapy.\n\n        Exclusion Criteria:\n\n          -  previous therapy which acts on EGFR axis;\n\n          -  clinical evidence of brain metastasis;\n\n          -  any unstable systemic disease;\n\n          -  unable to take oral medication;\n\n          -  any significant opthalmological abnormality."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "52", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "December 11, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02013206", 
            "org_study_id": "MO18660"
        }, 
        "intervention": [
            {
                "arm_group_label": "Never Smokers", 
                "description": "150 mg orally daily", 
                "intervention_name": "erlotinib [Tarceva]", 
                "intervention_type": "Drug", 
                "other_name": "Tarceva"
            }, 
            {
                "arm_group_label": "Current/former Smokers", 
                "description": "150 mg orally daily, increasing to a maximum of 300 mg orally daily", 
                "intervention_name": "erlotinib [Tarceva]", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Erlotinib"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "December 17, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Marseille", 
                        "country": "France", 
                        "zip": "13274"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Villejuif", 
                        "country": "France", 
                        "zip": "94805"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hamburg", 
                        "country": "Germany", 
                        "zip": "22045"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Milano", 
                        "country": "Italy", 
                        "zip": "20162"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rozzano", 
                        "country": "Italy", 
                        "zip": "20089"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Amsterdam", 
                        "country": "Netherlands", 
                        "zip": "1105 AZ"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Maastricht", 
                        "country": "Netherlands", 
                        "zip": "6229 HX"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Barcelona", 
                        "country": "Spain", 
                        "zip": "08035"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Barcelona", 
                        "country": "Spain", 
                        "zip": "08907"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Madrid", 
                        "country": "Spain", 
                        "zip": "28041"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Manchester", 
                        "country": "United Kingdom", 
                        "zip": "M2O 4BX"
                    }
                }
            }
        ], 
        "location_countries": {
            "country": [
                "France", 
                "Germany", 
                "Italy", 
                "Netherlands", 
                "Spain", 
                "United Kingdom"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "An Parallel Phase II Study of Tarceva (Erlotinib) in Patients With Advanced Non-small Cell Lung Cancer (Stage IIIB/IV) Not Pre-treated by Chemotherapy Including Dose Escalation to Toxicity in Current and Former Smokers.", 
        "overall_official": {
            "affiliation": "Hoffmann-La Roche", 
            "last_name": "Clinical Trials", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Austria: Austrian Federal Office for Safety in Health Care, BASG - AGES."
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2010", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Non-progression rate at 8 weeks", 
            "safety_issue": "No", 
            "time_frame": "Week 8"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02013206"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Objective response rate", 
                "safety_issue": "No", 
                "time_frame": "approximately 12 months"
            }, 
            {
                "measure": "Disease control rate", 
                "safety_issue": "No", 
                "time_frame": "approximately 12 months"
            }, 
            {
                "measure": "Duration of response", 
                "safety_issue": "No", 
                "time_frame": "approximately 18 months"
            }, 
            {
                "measure": "Time to progression", 
                "safety_issue": "No", 
                "time_frame": "approximately 18 months"
            }, 
            {
                "measure": "Progression-free survival", 
                "safety_issue": "No", 
                "time_frame": "approximately 18 months"
            }, 
            {
                "measure": "Overall survival", 
                "safety_issue": "No", 
                "time_frame": "approximately 18 months"
            }, 
            {
                "measure": "Safety: Incidence of adverse events", 
                "safety_issue": "No", 
                "time_frame": "approximately 18 months"
            }
        ], 
        "source": "Hoffmann-La Roche", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hoffmann-La Roche", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2006", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}